The Practical Cardiology™ Cardiovascular Disease clinical resource center hosts content related to a wide array of cardiovascular conditions. The leading cause of death in the United States, the term cardiovascular disease encompasses a multitude of conditions and this page serves as a hub for information to several of the most common conditions, including atherosclerotic cardiovascular disease, acute coronary syndromes, hypertension, and more.
December 02, 2022
Gregory Weiss, MD, provides insight into his perspective on the evolving recognition of the role of sleep health in cardiovascular disease prevention.
November 30, 2022
Leveraging data from the DASH trial, investigators from Beth Israel Deaconess Medical Center provides insight into the impact of different dietary approaches on 10-year ASCVD risk score among patients within the trial.
November 29, 2022
An analysis of self-reported dietary information from UK Biobank participants is providing insight into the effects of reducing added salt to foods on cardiovascular disease risk among adults without a history cardiovascular disease.
November 19, 2022
An analysis of data from 2010-2019 collected from 10 countries suggests influenza activity is responsible for 299k ischemic heart disease deaths per year on a global level.
November 18, 2022
Announced in a statement on November 17, the US FDA issued letters to 7 companies related to unsupported claims of supplements being able to cure, treat, mitigate or prevent cardiovascular disease or related conditions, such as atherosclerosis, stroke or heart failure, in violation of the Federal Food, Drug, and Cosmetic Act.
November 14, 2022
Data from the ATLAS trial indicate use of a subcutaneous ICD was associated with a 92% reduction in lead-related complications compared to TV-ICD without compromising the effectiveness of shocks, but investigators express caution over an increased incidence of inappropriate shocks with the S-ICD.
October 31, 2022
An analysis of trends in cardiovascular disease-related mortality from the US CDC WONDER database provides new insight into the apparent increases in mortality from cardiovascular disease observed during 2020 relative to the decreases in rate seen from 2010-2019.
October 29, 2022
The October 2022 cardiology month in review features the top content from HFSA 2022, new data related to antithrombotic therapy in atrial fibrillation, and shining a spotlight on the AHA’s scientific statement on patient-reported outcomes in peripheral artery disease.
October 05, 2022
Martin Maron, MD, sits down to discuss aficamten, the SEQUOIA-HCM trial, and the most pressing unmet needs in the management of hypertrophic cardiomyopathy.
October 02, 2022
Data presented at HFSA 2022 examining aficamten provides insight into the effects of the agent on LVOT-G, NYHA class, and KCCQ-OSS among patients with hypertrophic cardiomyopathy from the open-label extension trial.